目前,Excision正在对EBT-101进行更高剂量的测试,并在第二批病例中进行试验,同时探索可能比传统的腺相关病毒载体更高效的新CRISPR传递技术。其中一个可能的新方法是使用脂质纳米粒子,这种技术类似于COVID-19疫苗中用来传递信使RNA的方法。 信息来源:Pres...
目前,Excision正在对EBT-101进行更高剂量的测试,并在第二批病例中进行试验,同时探索可能比传统的腺相关病毒载体更高效的新CRISPR传递技术。其中一个可能的新方法是使用脂质纳米粒子,这种技术类似于COVID-19疫苗中用来传递信使RNA的方法。 信息来源:Presti R. First-in-human clinical trial of systemic CRISPR-CA9 mul...
Presti R. First-in-human clinical trial of systemic CRISPR-CA9 multiplex targeting of latent HIV. American Society of Gene & Cell Therapy, Baltimore, 2024. Excision BioTherapeutics. Excision BioTherapeutics announces data from the phase 1/2 trial of EBT-101 in hiv and in vivo efficacy data in ...
Excision BioTherapeutics, Inc. recently announced the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1). The participant was dosed in July 2022, with initial findings indicating EBT-10...
101 clinical trial, which is the first ever to evaluate anin vivoCRISPR-based therapy in an infectious disease. The grant will provide Excision with important funding to advance the trial and potentially...
a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced it will host a clinical expert webinar on HIV and the ongoing Phase 1/2 trial evaluating the Company’...
disease models and resulted in functional cures in transgenic mice. We are now working to build on these results through the advancement of EBT-101’s recently initiated Phase 1/2 clinical trial, and look...